Angiotensin II mediates hypertensive cardiac fibrosis via an Erbb4-IR-dependent mechanism.

Jian-Chun Li,Jian Jia,Li Dong,Zhong-Jing Hu,Xiao-Ru Huang,Hong-Lian Wang,Li Wang,Si-Jin Yang,Hui-Yao Lan
DOI: https://doi.org/10.1016/j.omtn.2023.06.017
2023-06-29
Abstract:TGF-β/Smad3 plays a vital role in hypertensive cardiac fibrosis. Long non-coding RNA (lncRNA) Erbb4-IR is a novel Smad3-dependent lncRNA that mediates kidney fibrosis. However, the role of Erbb4-IR in hypertensive heart disease remains unexplored, which was investigated in the present study by ultrasound-microbubble-mediated silencing cardiac Erbb4-IR in hypertensive mice induced by angiotensin-II. We found that chronic angiotensin II infusion induced hypertension and upregulated cardiac Erbb4-IR which was associated with cardiac dysfunction including the fall in the left ventricle ejection fraction (LVEF) and the LV fractional shortening (LVFS), and an increase in LV mass. Whereas knockdown of cardiac Erbb4-IR by Erbb4-IR shRNA gene transfer effectively improved the angiotensin II-induced deteriorations of cardiac functions although blood pressure was not altered. Furthermore, silencing cardiac Erbb4-IR also inhibited angiotensin-II-induced progressive cardiac fibrosis as evidenced by reduced collagen I and III, α-SMA, and fibronectin accumulation. Mechanistically, improved hypertensive cardiac injury by specifically silencing cardiac Erbb4-IR was associated with increased myocardial Smad7 and miR-29b , revealing that Erbb4-IR may target Smad7 and miR-29b to mediate angiotensin II-induced hypertensive cardiac fibrosis. In conclusion, Erbb4-IR is pathogenic in Ang II-induced cardiac remodeling and targeting Erbb4-IR may represent a novel therapy for hypertensive cardiovascular diseases.
medicine, research & experimental
What problem does this paper attempt to address?